274 related articles for article (PubMed ID: 8677458)
1. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1996 Jun; 23(3 Suppl 6):97-8. PubMed ID: 8677458
[TBL] [Abstract][Full Text] [Related]
2. Oral administration of mesna with ifosfamide.
Goren MP
Semin Oncol; 1996 Jun; 23(3 Suppl 6):91-6. PubMed ID: 8677457
[TBL] [Abstract][Full Text] [Related]
3. Combined intravenous and oral mesna in outpatients treated with ifosfamide.
Goren MP; McKenna LM; Goodman TL
Cancer Chemother Pharmacol; 1997; 40(5):371-5. PubMed ID: 9272112
[TBL] [Abstract][Full Text] [Related]
4. [Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
Matsumoto S; Kawaguchi N; Manabe J; Kuroda H; Shimoji T
Gan To Kagaku Ryoho; 1995 Jun; 22(7):965-8. PubMed ID: 7794006
[No Abstract] [Full Text] [Related]
5. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
[TBL] [Abstract][Full Text] [Related]
6. Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis.
Batista CK; Mota JM; Souza ML; Leitão BT; Souza MH; Brito GA; Cunha FQ; Ribeiro RA
Cancer Chemother Pharmacol; 2007 Jan; 59(1):71-7. PubMed ID: 16708234
[TBL] [Abstract][Full Text] [Related]
7. Comparision of uroprotective activity of reduced glutathione with mesna in ifosfamide induced hemorrhagic cystitis in rats.
Ali SA; Danda SK; Basha SA; Rasheed A; Ahmed O; Ahmed MM
Indian J Pharmacol; 2014; 46(1):105-8. PubMed ID: 24550594
[TBL] [Abstract][Full Text] [Related]
8. Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs.
Korkmaz A; Oter S; Deveci S; Goksoy C; Bilgic H
J Urol; 2001 Sep; 166(3):1119-23. PubMed ID: 11490309
[TBL] [Abstract][Full Text] [Related]
9. Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide.
Dornelas-Filho AF; Pereira VBM; Wong DVT; Nobre LMS; Melo AT; Silva CMS; Wanderley CWS; Nour ML; Araújo LCNC; Silva RO; Pinto FMM; Bingana RD; Souza MHLP; Alencar NMN; Silva PGB; Alves APNN; Almeida PRC; Cunha FQ; Lima-Júnior RCP
Int Immunopharmacol; 2018 Sep; 62():96-108. PubMed ID: 29990699
[TBL] [Abstract][Full Text] [Related]
10. Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis.
Matz EL; Hsieh MH
Urology; 2017 Feb; 100():16-19. PubMed ID: 27566144
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of ketamine against hemorrhagic cystitis in rats receiving ifosfamide.
Ozguven AA; Yılmaz O; Taneli F; Ulman C; Vatansever S; Onag A
Indian J Pharmacol; 2014; 46(2):147-51. PubMed ID: 24741183
[TBL] [Abstract][Full Text] [Related]
12. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
Sakurai M; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sano T; Suemasu K; Jett JR
Jpn J Clin Oncol; 1986 Jun; 16(2):153-6. PubMed ID: 3090314
[TBL] [Abstract][Full Text] [Related]
13. Nursing implications in the administration of ifosfamide and mesna.
Richters JE
Oncol Nurs Forum; 1990; 17(2):276. PubMed ID: 2107534
[No Abstract] [Full Text] [Related]
14. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
[TBL] [Abstract][Full Text] [Related]
16. Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis.
Lima MV; Ferreira FV; Macedo FY; de Castro Brito GA; Ribeiro RA
Cancer Chemother Pharmacol; 2007 Apr; 59(5):643-50. PubMed ID: 16947012
[TBL] [Abstract][Full Text] [Related]
17. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
Kuśnierczyk H; Konarski L; Kowalski P; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1997; 45(1):79-85. PubMed ID: 9090445
[TBL] [Abstract][Full Text] [Related]
18. U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
Cohen MH; Dagher R; Griebel DJ; Ibrahim A; Martin A; Scher NS; Sokol GH; Williams GA; Pazdur R
Oncologist; 2002; 7(5):393-400. PubMed ID: 12401901
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide and mesna.
Med Lett Drugs Ther; 1989 Nov; 31(804):98-9. PubMed ID: 2554100
[No Abstract] [Full Text] [Related]
20. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
